Xeris Biopharma (NASDAQ:XERS - Get Free Report) is set to announce its earnings results before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Xeris Biopharma has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. The company had revenue of $48.07 million for the quarter, compared to the consensus estimate of $46.80 million. During the same quarter last year, the firm posted ($0.14) earnings per share. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Xeris Biopharma Stock Up 0.3 %
Shares of NASDAQ XERS traded up $0.01 during trading on Friday, hitting $3.23. 685,446 shares of the company traded hands, compared to its average volume of 1,688,563. The firm has a market capitalization of $481.27 million, a P/E ratio of -7.51 and a beta of 2.76. The company has a 50-day moving average price of $2.91 and a 200-day moving average price of $2.44. Xeris Biopharma has a 1 year low of $1.46 and a 1 year high of $3.39.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Xeris Biopharma in a research note on Thursday, August 15th.
View Our Latest Analysis on XERS
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Further Reading
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
